Published: 2021-10-27

Prevalence of co-morbidities in hospitalized patients with COVID-19 in a COVID dedicated hospital

Kirti Vinayak Kinge, Smita Santosh Chavan, Balkrishna Adsul, Maharudra Kumbhar


Background: A novel corona virus causing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection become a public health emergency of international concern. The infection has increased and caused pandemic. Underlying co-morbidities may worsen the clinical outcome. So, more attention is to be given to COVID patients with co-morbidities. Few studies have been conducted on the prevalence of predominant chronic diseases with COVID-19. Taking into consideration the above factors, a study has been undertaken to assess the prevalence of co-morbidities in a COVID dedicated hospital.

Methods: A centre based retrospective study was carried out at a COVID dedicated hospital, Mumbai. All admitted patients of COVID 19 in a COVID dedicated hospital, Mumbai were selected in 4 and half months (19th March 2020 to 31st July 2020) by universal sampling technique. Patients above 20 years were included in the study and patients below 20 years were excluded from the study. Ethics Committee approval taken from an institutional ethics committee.

Results: All 6072 patients who were above 20 years were included in the study. Mean age was 48 years and 67.7% were male. The prevalence of various co-morbidities was 25% for hypertension, 22.3% for diabetes mellitus, 5.2% for chronic kidney disease, 1.7% for chronic obstructive pulmonary disease, 0.9% for cerebrovascular disease and 0.3% for one or the other malignancy.

Conclusions: It has been concluded that various co-morbidities are present in patients with COVID-19 which may worsen the clinical outcome. So, more attention is to be given to COVID patients with co-morbidities.


Co-morbidities, COVID-19, Prevalence

Full Text:



Tan W, Zhao X, Ma X, Wang W, Niu P, Xu W, et al. A novel coronavirus genome identified in a cluster of pneumonia cases-Wuhan, China 2019- 2020. China CDC Weekly. 2020;2(4):61-2.

Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-13.

Carlos WG, Dela Cruz CS, Cao B, Pasnick S, Jamil S. Novel Wuhan (2019-nCoV) Coronavirus. Am J Respir Crit Care Med. 2020;201(4):P7-8.

Paules CI, Marston HD, Fauci AS. Coronavirus infections- more than just the common cold. JAMA. 2020;323(8):707-8.

Livingston E, Bucher K, Rekito A. Coronavirus disease 2019 and influenza 2019-2020. JAMA. 2020;323(12):1122.

Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2020;395(10223):470-3.

Rodríguez-Morales AJ, MacGregor K, Kanagarajah S, Patel D, Schlagenhauf P. Going global- travel and the 2019 novel coronavirus. Travel Med Infect Dis. 2020;33:101578.

Sun K, Chen J, Viboud C. Early epidemiological analysis of the coronavirus disease 2019 outbreak based on crowd sourced data: a population-level observational study. Lancet Digital Health. 2020;2(4):e201-8.

Zu ZY, Jiang MD, Xu PP, Chen W, Ni QQ, Lu GM, et al. Coronavirus disease 2019 (COVID-19): a perspective from China. Radiology. 2020;296(2):E15-25.

Peng L, Yang W, Zhang D, Zhuge C, Hong L. Epidemic analysis of COVID-19 in China by dynamical modelling. arXiv preprint arXiv:200206563. 2020.

Kui L, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chinese Med J. 2020;133(9):1025.

Xiao-Wei X, Xiao-Xin W, Xian-Gao J, Kai-Jin X, Ling-Jun Y, Chun-Lian M, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARSCov-2) outside of Wuhan, China: retrospective case series. Br Med J. 2020;368.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus- infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-9.

Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China. Allergy. 2020;75(7):1730-41.

Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335-7.

Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-20.

Guarner J. Three emerging coronaviruses in two decades the story of SARS, MERS, and now COVID-19. Am J Clin Pathol. 2020;153(4):420-1.

Wu J, Liu J, Zhao X, Liu C, Wang W, Wang D, et al. Clinical characteristics of imported cases of COVID-19 in Jiangsu province: a multicenter descriptive study. Clin Infect Dis. 2020;10.

Seys LJM, Widagdo W, Verhamme FM, Kleinjan A, Janssens W, Joos GF, et al. DPP4, the Middle East respiratory syndrome coronavirus receptor, is upregulated in lungs of smokers and chronic obstructive pulmonary disease patients. Clin Infect Dis. 2018;66(1):45-53.

Van Gerwen M, Alsen M, Little C, Barlow J, Naymagon L, Tremblay D, et al. Outcomes of patients with hypothyroidism and COVID-19: a retrospective cohort study. Front Endocrinol. 2020;11:565.